Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Bush

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Translational Oncology|August 31, 2020
Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancerCandace M Howard, Nadim Bou Zgheib, Stephen Bush, et al.
Scientific Reports|November 10, 2022
Real-world clinical effectiveness and sustainability of universal bloodborne virus testing in an urban emergency department in the UKElizabeth Smout, Khine Phyu, Gareth J Hughes, et al.
Plos One|November 19, 2013
Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancerJinhua Wang, Ashok Sharma, Sharad A Ghamande, et al.
NPJ Precision Oncology|March 26, 2025
ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trialThomas J Herzog, Thomas C Krivak, Stephen Bush, et al.
Oncotarget|May 2, 2019
Clinical validation of the tempus xT next-generation targeted oncology sequencing assayNike Beaubier, Robert Tell, Denise Lau, et al.
Nature Biotechnology|October 2, 2019
Integrated genomic profiling expands clinical options for patients with cancerNike Beaubier, Martin Bontrager, Robert Huether, et al.
Oncotarget|June 15, 2018
Clinical validation of the Tempus xO assayNike Beaubier, Robert Tell, Robert Huether, et al.
Journal of Molecular Biology|October 18, 2011
Community-wide assessment of protein-interface modeling suggests improvements to design methodologySarel J Fleishman, Timothy A Whitehead, Eva-Maria Strauch, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Translational Oncology|August 31, 2020
Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancerCandace M Howard, Nadim Bou Zgheib, Stephen Bush, et al.
Scientific Reports|November 10, 2022
Real-world clinical effectiveness and sustainability of universal bloodborne virus testing in an urban emergency department in the UKElizabeth Smout, Khine Phyu, Gareth J Hughes, et al.
Plos One|November 19, 2013
Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancerJinhua Wang, Ashok Sharma, Sharad A Ghamande, et al.
NPJ Precision Oncology|March 26, 2025
ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trialThomas J Herzog, Thomas C Krivak, Stephen Bush, et al.
Oncotarget|May 2, 2019
Clinical validation of the tempus xT next-generation targeted oncology sequencing assayNike Beaubier, Robert Tell, Denise Lau, et al.
Nature Biotechnology|October 2, 2019
Integrated genomic profiling expands clinical options for patients with cancerNike Beaubier, Martin Bontrager, Robert Huether, et al.
Oncotarget|June 15, 2018
Clinical validation of the Tempus xO assayNike Beaubier, Robert Tell, Robert Huether, et al.
Journal of Molecular Biology|October 18, 2011
Community-wide assessment of protein-interface modeling suggests improvements to design methodologySarel J Fleishman, Timothy A Whitehead, Eva-Maria Strauch, et al.
Pageof 3